secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nemaura Medical Inc. (—)
CIK:        0001602078
Form:       8-K/A
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001079973-23-000239
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nemaura Medical restates Q1 and Q2 FY2022 financials; net loss decreased by up to $313k
--------------------------------------------------------------------------------

- Non-reliance on Q1 and Q2 FY2022 10-Qs due to errors in foreign currency translation and debt issuance costs.
- Net loss for Q1 FY2022 decreased by $90k to ~$3.889M; Q2 FY2022 decreased by $223k to ~$3.856M; six months decreased by $313k to ~$7.745M.
- Material weakness in internal controls over financial reporting identified; disclosure controls not effective.
- Q3 FY2022 10-Q (for period ended Dec 31, 2022) expected to be delayed beyond Feb 21, 2023 deadline.
- Errors do not impact previously reported sales, gross profit, or cash positions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1602078/000107997323000239/0001079973-23-000239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1602078/000107997323000239/nmra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-23-000239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer